Research programme: anti-cancer therapeutics - ConverGeneAlternative Names: CG-223; CG-250
Latest Information Update: 31 Jan 2017
At a glance
- Originator ConverGene
- Developer ConverGene; University of Maryland School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Dopamine D2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours